Results 201 to 210 of about 63,268 (276)

Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. [PDF]

RMD Open
Maksymowych WP, Yeshokumar A, Cerullo E, Lambert RGW, Śliwinska-Stańczyk P, Klimiuk P, Kepich R, Pachai C, Zhu M, Liu J, Landis J, Goti V, Greenberg S.   +12 more
europepmc   +1 more source

Clinical efficacy of tofacitinib in active ankylosing spondylitis and dynamic changes in gut microbiota: an exploratory descriptive four-case series with 16S rRNA sequencing analysis. [PDF]

Front Immunol
Wang L, Xie W, Li J, Chen J, Huang Y.
europepmc   +1 more source

Identifying Flare Prone Spondyloarthritis: Insights From a Prospective Cohort. [PDF]

Cureus
Krishnan V A, Mukherjee S, Maurya MK, Dhakad U, Kamble N, Pm A, Singh A, Kumar P.   +7 more
europepmc   +1 more source

The synergistic ototoxicity of adalimumab combined with methotrexate in the treatment of ankylosing spondylitis. [PDF]

Front Neurol
Wei H, Xu C.
europepmc   +1 more source

Case reports: Pulmonary destructive lesions caused by ankylosing spondylitis. [PDF]

J Clin Tuberc Other Mycobact Dis
Zhan S, Zhang H, Peng Q, Qin H, Zhang P.
europepmc   +1 more source

Morphea Induced by Golimumab in a Patient With Ankylosing Spondylitis: A Case Report and Literature Review. [PDF]

Clin Case Rep
Hilwanjee F, Alghabra Y, Aldalati R, Al Chama N.   +3 more
europepmc   +1 more source

Mechanistic insights into how gut homeostasis and immune-system crosstalk shape ankylosing spondylitis. [PDF]

Front Immunol
Li J, Xie X.
europepmc   +1 more source

EQTL analyses are a formidable tool to define the immunogenetic mechanisms underpinning Spondyloarthropathies

Frontiers in Immunology
Matteo Vecellio, Matteo Vecellio, Carlo Selmi, Carlo Selmi   +3 more
doaj   +1 more source

Spondylitis in Twins [PDF]

Proceedings of the Royal Society of Medicine, 1932
openaire   +2 more sources